mRNA / LNP CDMOs — Ranked by Signal Score · 2026
mRNA / LNP manufacturers on CDMO Signal: 40 listed. 7 are fully evidenced (all four Signal Score pillars and at least one ClinicalTrials.gov match). The highest Signal Scores in that fully evidenced set are Pfizer CentreOne (also makes its own products, Signal Score 90.1), BioNTech (Mfg Services) (also makes its own products, Signal Score 82.1) and Merck KGaA / MilliporeSigma (CDMO) (also makes its own products, Signal Score 81.9). Outside that set, higher Signal Scores on this list include FUJIFILM Diosynth Biotechnologies (Signal Score 86.7), Corden Pharma (Signal Score 83.1) and ReciBioPharm (Signal Score 82.9). A higher score there is not a fully evidenced record. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.
mRNA/LNP CDMOs with the most regulatory evidence on file
mRNA and lipid nanoparticle (LNP) manufacturing scaled rapidly after COVID-19 vaccines and now supports therapeutics across rare disease, oncology, and infectious disease. The platform pairs IVT mRNA synthesis with LNP formulation — two distinct capability sets.
Choosing an mRNA/LNP CDMO depends on IVT scale, template strategy (linearized plasmid vs PCR), LNP formulation and microfluidics, and cold-chain handling. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 21 NAI (no action), 44 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: United States (50), Germany (42), Denmark (29), UNITED KINGDOM (22), Italy (21).
Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing contract manufacturers only.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
PC
|
90.1 | 100.0 | 4 insp · 14 GMP | 2025-12-16 · NAI | — | 366 programs |
| 2 |
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
|
86.7 | 100.0 | 0 insp · 35 GMP | None on file | — | |
| 3 |
CD
Plankstadt, DE · Caponago, IT · Boulder, CO
|
83.1 | 99.3 | 5 insp · 17 GMP | 2025-11-14 · NAI | — | — |
| 4 |
RP
Keele, UK · Sodertalje, SE
|
82.9 | 100.0 | 0 insp · 3 GMP | None on file | — | — |
| 5 |
WK
Jena, DE · Amsterdam, NL · San Diego, CA
|
82.9 | 100.0 | 1 insp · 13 GMP | 2023-12-07 · VAI | — | — |
| 6 |
BNT
|
82.1 | 100.0 | 0 insp · 8 GMP | None on file | — | 28 programs |
| 7 |
MK
Darmstadt, DE · St. Louis, MO
Hiring · 8 open roles
Fully evidenced
Also makes its own products
|
81.9 | 98.8 | 2 insp · 2 GMP | 2025-04-28 · VAI | — | 22 programs |
| 8 |
KE
Seraing, BE
|
81.6 | 99.9 | 1 insp · 4 GMP | 2024-02-26 · VAI | — | — |
| 9 |
EK
Birmingham, AL · Vancouver, BC
|
81.5 | 99.8 | 2 insp · 2 GMP | 2025-09-11 · NAI | — | — |
| 10 |
ND
Milford, MA
|
80.3 | 100.0 | 4 insp · 0 GMP | 2026-08-12 · NAI | — | — |
| 11 |
AE
|
80.3 | 100.0 | 1 insp · 0 GMP | 2024-11-08 · NAI | — | — |
| 12 |
CRA
|
79.5 | 100.0 | 2 insp · 18 GMP | 2025-12-02 · NAI | — | — |
| 13 |
UM
Boston, MA
|
78.7 | 96.7 | 2 insp · 0 GMP | 2025-12-18 · VAI | — | — |
| 14 |
|
76.1 | 77.3 | 24 insp · 39 GMP | 2026-05-22 · VAI Warning letter 2025-11-20 |
— | — |
| 15 |
CVC
|
75.3 | 100.0 | 0 insp · 7 GMP | None on file | — | 4 programs |
| 16 |
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
|
73.6 | 95.6 | 1 insp · 0 GMP | 2025-01-21 · VAI | Available | 9 programs |
| 17 |
|
72.8 | 86.6 | 11 insp · 8 GMP | 2025-09-29 · VAI | — | 1 program |
| 18 |
PBI
Pennington, NJ · Nanjing, CN
|
64.0 | — | — | None on file | — | — |
| 19 |
HP
Amer, Spain
|
63.0 | — | — | None on file | — | — |
| 20 |
SB
|
61.5 | — | — | None on file | Available | — |
| 21 |
AT
|
60.5 | — | — | None on file | — | — |
| 22 |
RR
Guangzhou, China
|
59.0 | — | — | None on file | — | — |
| 23 |
SP
Seoul, South Korea
|
59.0 | — | — | None on file | — | — |
| 24 |
EH
|
56.5 | — | — | None on file | — | — |
| — |
Frankfurt am Main, Germany
|
Profiled | — | 1 insp · 0 GMP | 2022-11-15 · VAI | — | — |
| — |
Austria
|
Profiled | — | 0 insp · 5 GMP | None on file | — | — |
| — |
|
Profiled | — | 1 insp · 0 GMP | 2025-11-14 · VAI | — | — |
| — |
|
Profiled | — | 1 insp · 0 GMP | 2023-07-07 · VAI | — | — |
| — |
|
Profiled | — | — | None on file | — | — |
| — |
Knoxville, Tennessee, USA
|
Profiled | — | — | None on file | — | — |
| — |
Bloomington, Indiana, USA
|
Profiled | — | — | None on file | — | — |
| — |
North Brunswick, New Jersey, USA
|
Profiled | — | — | None on file | — | — |